Researchers claim that STN-DBS has been demonstrated to sustain effectiveness in patients up to 11 years after surgery and is associated with various favorable outcomes in patients with PD, including a decreased risk of disease progression.  DBS, however, may lose effectiveness with time, according to contradictory data.